ABSTRACTS Accepted for POSTER PRESENTATIONS 58th Annual Cancer Symposium Society of Surgical Oncology March 3â6, 2005 Atlanta, GA P1 A novel flow cytometric assay for measurement of phosphorylated STAT5 in peripheral blood mononuclear cells of melanoma patients receiving Interleukin-2 K.A. Varker,1* M.R. Go,2 G.B. Lesinski,3 S.V Kondadasula,3 J.P. Monk,4 W.E. Carson, III.2 1. Comprehensive . Cancer Center, The Ohio State University, Columbus, OH; 2. Department of Surgery, The Ohio State University, Columbus, OH; 3. Department of Human Cancer Genetics, The Ohio State University, Columbus, OH; 4. Department of Medical Oncology, The Ohio State University, Columbus, OH. Introduction: Treatment of patients with metastatic malignant melanoma with Interleukin-2 (IL-2) achieves clinical response rates of 10-20%. One-third of these patients will experience a durable response. IL-2 is known to activate the transcription factor signal transducer and activator of transcription 5 (STAT5) by phosphorylation (P). We developed a novel flow cytometric assay to measure the phosphorylation of STAT5 in the peripheral blood mononuclear cells (PBMC) of patients receiving IL-2 treatment. Methods: PBMC were obtained from 5 patients with advanced renal cell carcinoma undergoing treatment with high-dose IL-2. Patient samples were drawn immediately before and 30 minutes after IL-2 administration. PBMC from healthy
/lp/springer-journals/abstracts-accepted-for-poster-presentations-1yAjk8SXI0